EventsThe 3rd International Electronic Conference on Biomedicines
Published
This submission belongs to the session S2. Immunotherapy and Adverse Effects of the event The 3rd International Electronic Conference on Biomedicines
Published date
13 May, 2025
Academic Editor
author-avatarGeorgia Levidou
Citation
Firoaguer Isaure, Conte Samantha, Lledo Simon, Tran Thi Tom, El Yazidi Claire, Chevillard Christophe, Guieu Régis, Puthier Denis, Fenouillet Emmanuel, Thuny Franck, Cautela Jenifer, Lalevée Nathalie, Transcriptional Impact of Pro-Inflammatory Cytokines in hiPSC-Derived Endothelial Cells and Cardiomyocytes: Insights into ICI-Induced Myocarditis, in Proceedings of The 3rd International Electronic Conference on Biomedicines, 12 May–15 May 2025, MDPI: Basel, Switzerland
Share
Email
Facebook
Twitter
LinkedIn

Transcriptional Impact of Pro-Inflammatory Cytokines in hiPSC-Derived Endothelial Cells and Cardiomyocytes: Insights into ICI-Induced Myocarditis

Conte Samantha 1,2
Tran Thi Tom 1,2
image
Fenouillet Emmanuel 1,2
Thuny Franck 1,2,7
Cautela Jenifer 1,2,7
1. Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France, France
2. Aix Marseille Univ, MarMaRa Institute, Marseille, France
3. Aix Marseille Univ, MarMaRa Institute, Marseille, France, France
4. Aix Marseille Univ, INSERM, MMG, Marseille, France
5. Aix Marseille Univ, INSERM, TAGC, Marseille, France
6. Laboratory of Biochemistry, Timone Hospital, Marseille
7. Aix Marseille Univ, AP-HM, North Hospital, Department of Cardiology, Medi-CO Center, Marseille, France
Abstract

Introduction: Inflammatory cytokines, particularly IFN-γ, are highly elevated in biopsies and the peripheral blood of patients with ICI-induced myocarditis (ICI-M). While the NLRP3 inflammasome has been implicated in ICI-M pathophysiology, its underlying mechanisms remain poorly understood.

Objective: This study investigates the transcriptional effects of inflammatory cytokines associated with ICI-M on endothelial cells (hiPSC-EC) and cardiomyocytes (hiPSC-CM) derived from a healthy individual’s hiPSC clone.

Method: The transcriptional profiles of both the hiPSC-derived endothelial cells (hiPSC-EC) and cardiomyocytes (hiPSC-CM) were analyzed following the IFN-γ treatment. Inflammatory responses, cell mortality, and apoptosis were assessed after stimulation with pro-inflammatory molecules, either through individual IFN-γ exposure or a combined cytokine cocktail (CCL5, GZMB, IL-1β, IL-2, IL-6, IFN-γ, and TNF-α), to characterize their effects on cellular function and viability better.

Results: Our findings reveal that hiPSC-ECs are highly sensitive to cytokine treatment, exhibiting significant mortality and marked transcriptomic changes in immunity- and inflammation-related pathways. In contrast, hiPSC-CMs show lower transcriptomic alterations, reduced mortality, and less apoptosis. In both cell types, cytokine treatment upregulates key components of the NLRP3 inflammasome pathway, including regulators (GBP5, GBP6, P2X7, NLRC5), a core component (AIM2), and an effector (GSDMD). Notably, cytokine treatment increases the GBP5 protein expression and CASP-1 cleavage in hiPSC-CMs, mirroring observations in endomyocardial biopsies from ICI-M patients.

Conclusion: This cellular model provides valuable insights into endocardial and microvascular dysfunctions in inflammatory conditions and their impact on cardiomyocytes. These findings establish a robust experimental model for investigating the response of hiPSC-derived cardiac cells to inflammatory cytokines implicated in immuno-mediated myocarditis. Moreover, they provide essential reference values for comparative studies using hiPSC clones derived from affected patients, thereby facilitating a deeper understanding of the disease mechanisms.

Keywords
Inflammatory cytokines
hiPSC-EC
hiPSC-CM
ICI-induced myocarditis model
NLRP3 inflammasome
Oral Presentation
Neuroprotective Effects of the Flowers of Camellia japonica var. Hagoromo: A Potential Candidate for Neurodegenerative Disease Treatment
Efficacy of Liposome-Encapsulated Doxycycline Against Methicillin-Resistant Staphylococcus aureus